Pietro A Canetta

List of Publications by Year
in descending order

60 papers	4,369 citations	218677 26 h-index	168389 53 g-index
61 all docs	61 docs citations	61 times ranked	5395 citing authors

#	Article	IF	Citations
1	Sensitivity and Specificity of a Single Emergency Department Measurement of Urinary Neutrophil Gelatinaseâ€“Associated Lipocalin for Diagnosing Acute Kidney Injury. Annals of Internal Medicine, 2008, 148, 810.	3.9	597
2	Diagnostic Utility of Exome Sequencing for Kidney Disease. New England Journal of Medicine, 2019, 380, 142-151.	27.0	456
3	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 36-46.	27.0	324
4	Diagnostic and Prognostic Stratification in the Emergency Department Using Urinary Biomarkers of Nephron Damage. Journal of the American College of Cardiology, 2012, 59, 246-255.	2.8	306
5	Kidney Biopsy Findings in Patients with COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 1959-1968.	6.1	301
6	Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 748-756.	4.5	295
7	Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney International Reports, 2020, 5, 940-945.	0.8	182
8	A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American Society of Nephrology: JASN, 2017, 28, 1306-1313.	6.1	174
9	Whole-Exome Sequencing in Adults With Chronic Kidney Disease. Annals of Internal Medicine, 2018, 168, 100.	3.9	154
10	C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney International, 2018, 93, 977-985.	5.2	123
11	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	12.8	120
12	Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1595-1602.	4.5	103
13	Rationale and design of the Kidney Precision Medicine Project. Kidney International, 2021, 99, 498-510.	5.2	94
14	Treatment of Idiopathic FSGS with Adrenocorticotropic Hormone Gel. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 2072-2081.	4.5	86
15	Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies. Nephrology Dialysis Transplantation, 2018, 33, 310-318.	0.7	85
16	Treatment of Resistant Glomerular Diseases with Adrenocorticotropic Hormone Gel: A Prospective Trial. American Journal of Nephrology, 2012, 36, 58-67.	3.1	83
17	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	1.9	68
18	Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 406-413.	4.5	63

#	Article	IF	Citations
19	A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron, 2015, 130, 159-168.	1.8	49
20	Kidney Transplantation in C3 Glomerulopathy: A Case Series. American Journal of Kidney Diseases, 2019, 73, 316-323.	1.9	48
21	Rituximab treatment for fibrillary glomerulonephritis. Nephrology Dialysis Transplantation, 2014, 29, 1925-1931.	0.7	47
22	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39
23	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38
24	Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. Journal of the American Society of Hypertension, 2012, 6, 338-345.	2.3	35
25	Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents. American Journal of Nephrology, 2017, 45, 99-106.	3.1	35
26	Longitudinal Outcomes of COVID-19â€“Associated Collapsing Glomerulopathy and Other Podocytopathies. Journal of the American Society of Nephrology: JASN, 2021, 32, 2958-2969.	6.1	31
27	The clinicopathologic spectrum of segmental membranous glomerulopathy. Kidney International, 2021, 99, 247-255.	5.2	30
28	Glomerular Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 617-625.	4.5	28
29	Pilot Study of Return of Genetic Results to Patients in Adult Nephrology. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 651-664.	4.5	28
30	Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity. Aids, 2015, 29, 941-946.	2.2	26
31	Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. Nephrology Dialysis Transplantation, 2013, 28, 1371-1376.	0.7	25
32	Lack of Serologic Evidence to Link IgA Nephropathy with Celiac Disease or Immune Reactivity to Gluten. PLoS ONE, 2014, 9, e94677.	2.5	25
33	Rationale and design of the Transformative Research in Diabetic NephropathyÂ(TRIDENT) Study. Kidney International, 2020, 97, 10-13.	5.2	23
34	How COVID-19 Has Changed the Management of Glomerular Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 876-879.	4.5	23
35	The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome. Frontiers in Pediatrics, 2015, 3, 78.	1.9	21
36	Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis. Kidney International, 2021, 100, 672-683.	5.2	21

#	Article	IF	Citations
37	Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney injury (AKI) diagnosis. PLoS ONE, 2017, 12, e0178091.	2.5	21
38	An Open-Label Pilot Study ofÂAdrenocorticotrophic Hormone inÂtheÂTreatment of IgA Nephropathy atÂHigh Risk of Progression. Kidney International Reports, 2020, 5, 58-65.	0.8	17
39	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.8	17
40	Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. Kidney International, 2021, 100, 440-446.	5.2	17
41	Concurrent Antiâ€“Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series. American Journal of Kidney Diseases, 2021, 78, 219-225.e1.	1.9	16
42	Use of Bortezomib in Heavy-Chain Deposition Disease:ÂAÂReportÂof 3 Cases. American Journal of Kidney Diseases, 2014, 64, 123-127.	1.9	15
43	Diagnostic Approach to Glomerulonephritis With Fibrillar IgG Deposits and Light Chain Restriction. Kidney International Reports, 2021, 6, 936-945.	0.8	14
44	A 56-year-old woman with sarcoidosis and acute renal failure. Kidney International, 2008, 74, 817-821.	5.2	13
45	Predictors of outcome for severe IgA Nephropathy in a multi-ethnic U.S. cohort. Clinical Nephrology, 2015, 84 (2015), 145-155.	0.7	13
46	Clinical Predictors and Prognosis of Recurrent IgA Nephropathy in the Kidney Allograft. Glomerular Diseases, 2022, 2, 42-53.	1.0	9
47	Glomerular Diseases in Patients with Diabetes Mellitus: An Underappreciated Epidemic. Kidney360, 2020, 1, 220-222.	2.1	9
48	Impact of the National Institutes of Health Focal Segmental Glomerulosclerosis (NIH FSGS) clinical trial on the treatment of steroid-resistant FSGS. Nephrology Dialysis Transplantation, 2013, 28, 527-534.	0.7	8
49	Patient perspectives and involvement in precision medicine research. Kidney International, 2021, 99, 511-514.	5.2	5
50	A Participant-Centered Approach to Understanding Risks and Benefits of Participation in Research Informed by the Kidney Precision Medicine Project. American Journal of Kidney Diseases, 2022, 80, 132-138.	1.9	3
51	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. Kidney International Reports, 2020, 5, 860-871.	0.8	2
52	Toward a Clearer Picture of IgA Nephropathy in Spondyloarthritis. Kidney International Reports, 2020, 5, 766-768.	0.8	1
53	New and emerging treatments for lupus nephritis. Dialysis and Transplantation, 2011, 40, 67-71.	0.2	0
54	Su1445 Lack of Serologic Evidence for an Association Between Gluten Sensitivity and IgA Nephropathy. Gastroenterology, 2014, 146, S-471.	1.3	0

#	Article	IF	Citations
55	Idiopathic Immune Complex Glomerulonephritis. , 2017, , 1-10.		0
56	A Case of Iatrogenic Dehydration. American Journal of Kidney Diseases, 2019, 74, A15-A18.	1.9	0
57	Ask and It Shall Be Given. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 594-596.	4.5	0
58	Late Relapses of Membranous Nephropathy: A Case Series. Kidney360, 2021, 2, 974-982.	2.1	0
59	Mixed Cryoglobulinemia. , 2017, , 1-13.		0
60	Disentangling a Case of Glomerulonephritis with Fibrils. Clinical Journal of the American Society of Nephrology: CJASN, 0, , CJN.00630122.	4.5	0